Research programme: CNS disease therapeutics - Bristol-Myers Squibb

Drug Profile

Research programme: CNS disease therapeutics - Bristol-Myers Squibb

Alternative Names: Disease activated CNS therapeutics; pH-activated CNS therapeutics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeurOp
  • Developer Bristol-Myers Squibb; NeurOp
  • Class Small molecules
  • Mechanism of Action NR2B N-Methyl D-Aspartate receptor modulators; NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cerebral ischaemia; Major depressive disorder; Pain

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cerebral-ischaemia(Prevention) in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder(Treatment-resistant) in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top